Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
PFE | 55.88% | $137.53B | -13.55% | 7.04% |
MTD | 51.39% | $24.62B | -15.24% | 0.00% |
AMGN | 49.60% | $149.01B | -11.30% | 3.34% |
RYN | 47.52% | $3.45B | -23.96% | 5.01% |
TMO | 46.75% | $154.12B | -26.17% | 0.40% |
WY | 46.69% | $18.75B | -8.95% | 3.16% |
TECH | 45.47% | $8.13B | -27.65% | 0.62% |
NVS | 45.26% | $227.73B | +12.73% | 3.32% |
JNJ | 44.54% | $366.71B | +4.28% | 3.30% |
MKC | 44.44% | $20.47B | +7.57% | 2.29% |
ES | 44.20% | $23.28B | +11.73% | 4.65% |
PCH | 43.22% | $3.06B | -1.27% | 4.63% |
GILD | 42.99% | $137.67B | +61.30% | 2.84% |
SPNS | 42.95% | $1.61B | -14.06% | 2.02% |
MRK | 42.59% | $198.62B | -36.11% | 4.04% |
NSA | 42.49% | $2.43B | -22.80% | 7.15% |
AVB | 42.41% | $29.10B | -1.21% | 3.39% |
CPT | 42.40% | $12.15B | +4.26% | 3.65% |
DOC | 42.11% | $12.06B | -11.43% | 6.99% |
DHR | 41.92% | $142.28B | -20.43% | 0.73% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
AMTX | 0.04% | $130.12M | -21.93% | 0.00% |
DAKT | 0.08% | $765.68M | +11.76% | 0.00% |
VLRS | -0.08% | $537.07M | -26.57% | 0.00% |
SSYS | 0.09% | $941.26M | +33.49% | 0.00% |
BLKB | 0.10% | $3.11B | -15.89% | 0.00% |
LFWD | 0.11% | $7.77M | -83.29% | 0.00% |
PWR | 0.16% | $56.50B | +50.05% | 0.10% |
PSTG | 0.17% | $18.11B | -13.72% | 0.00% |
AGRO | 0.22% | $905.94M | -6.89% | 3.85% |
ALNT | 0.24% | $608.09M | +42.14% | 0.33% |
PLCE | 0.25% | $98.20M | -45.58% | 0.00% |
WRAP | 0.27% | $79.91M | -21.00% | 0.00% |
ANAB | 0.29% | $660.18M | -10.34% | 0.00% |
ABCL | 0.31% | $1.08B | +21.96% | 0.00% |
FUBO | -0.32% | $1.21B | +184.68% | 0.00% |
LITB | -0.38% | $21.70M | -78.27% | 0.00% |
ACEL | -0.40% | $1.01B | +15.98% | 0.00% |
RLX | -0.41% | $2.02B | +20.65% | 0.45% |
RIOT | -0.42% | $3.77B | +15.43% | 0.00% |
STN | 0.43% | $12.50B | +31.15% | 0.56% |
Finnhub
AbbVie announces that it has entered into a definitive agreement to acquire Capstan Therapeutics, including CPTX2309, currently in Phase 1 development for the treatment of B-cell-mediated autoimmune...
Finnhub
By Denny Jacob AbbVie agreed to acquire Capstan Therapeutics, including its lead asset, for $2.1 billion in cash. The North Chicago, Ill., drugmaker's planned acquisition includes CPTX2309,...
Finnhub
June 30 - U.S. drugmaker AbbVie said on Monday it willacquire cell therapy developer Capstan Therapeutics in a cashdeal worth up to $2.1 billion, expanding its pipeline...
Finnhub
June 30 - U.S. drugmaker AbbVie said on Monday it willacquire cell therapy developer Capstan Therapeutics in a cashdeal worth up to $2.1 billion. Capstan develops CAR-T...
Finnhub
AbbVie Inc. dropped from Russell 3000E Value Index...
Finnhub
AbbVie Inc. dropped from Russell Top 200 Value Index...
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
AGL | -14.67% | $956.23M | -64.68% | 0.00% |
RDNT | -12.12% | $4.29B | -3.06% | 0.00% |
BTCT | -10.76% | $18.98M | +37.85% | 0.00% |
NATR | -10.63% | $267.72M | -3.78% | 0.00% |
GALT | -10.49% | $147.47M | +3.10% | 0.00% |
STRL | -9.28% | $7.04B | +95.63% | 0.00% |
AIFU | -9.13% | $6.13B | +82.50% | 0.00% |
BTBT | -9.08% | $419.15M | -36.79% | 0.00% |
COIN | -8.76% | $90.02B | +59.04% | 0.00% |
HNRG | -8.64% | $659.25M | +97.43% | 0.00% |
CCRN | -8.48% | $419.30M | -7.59% | 0.00% |
CANG | -8.24% | $300.13M | +167.07% | 0.00% |
IREN | -7.61% | $3.37B | +24.00% | 0.00% |
ORN | -7.52% | $359.94M | -4.31% | 0.00% |
TLN | -7.51% | $13.56B | +168.31% | 0.00% |
ZVIA | -7.47% | $240.48M | +439.10% | 0.00% |
MSTR | -7.37% | $104.95B | +178.68% | 0.00% |
GIFI | -6.62% | $110.16M | +11.86% | 0.00% |
CRMD | -6.53% | $847.81M | +188.68% | 0.00% |
FARO | -6.21% | $849.75M | +174.94% | 0.00% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
FXE | -0.04% | $568.58M | 0.4% |
BOXX | -0.11% | $6.72B | 0.19% |
BLOK | 0.13% | $1.05B | 0.76% |
IBDQ | 0.50% | $3.00B | 0.1% |
ULST | -0.51% | $662.59M | 0.2% |
UTWO | 0.53% | $379.36M | 0.15% |
CORN | 0.53% | $44.21M | 0.2% |
IBTH | 0.66% | $1.60B | 0.07% |
ASHR | 0.92% | $1.91B | 0.65% |
FXY | 0.92% | $815.67M | 0.4% |
SPTS | -0.92% | $5.78B | 0.03% |
TBLL | -0.95% | $2.14B | 0.08% |
BTAL | -1.09% | $296.79M | 1.43% |
URNM | 1.15% | $1.74B | 0.75% |
CNYA | 1.43% | $206.04M | 0.6% |
PALL | -1.51% | $494.87M | 0.6% |
VGSH | 1.66% | $22.80B | 0.03% |
UNG | -1.70% | $359.91M | 1.06% |
UUP | -1.83% | $237.02M | 0.77% |
KCCA | 1.89% | $104.88M | 0.87% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
VIXY | -27.21% | $165.69M | 0.85% |
TAIL | -24.63% | $99.76M | 0.59% |
CLIP | -17.16% | $1.52B | 0.07% |
IVOL | -15.00% | $351.30M | 1.02% |
TPMN | -10.93% | $30.77M | 0.65% |
DEFI | -10.05% | $14.62M | 0.94% |
TESL | -9.94% | $32.78M | 1.2% |
BTC | -8.97% | $4.74B | 0.15% |
FTSD | -8.64% | $231.79M | 0.25% |
CONY | -8.57% | $1.49B | 1.22% |
BRRR | -8.32% | $629.51M | 0.25% |
HODL | -8.18% | $1.68B | 0.25% |
IBIT | -8.18% | $74.65B | 0.25% |
FBTC | -8.16% | $21.49B | 0.25% |
BITO | -8.15% | $2.55B | 0.95% |
GBTC | -8.07% | $19.96B | 1.5% |
BTCO | -8.02% | $555.61M | 0.39% |
ARKB | -8.01% | $4.88B | 0.21% |
BITB | -7.99% | $4.24B | 0.2% |
EZBC | -7.79% | $551.19M | 0.29% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
FDL | 62.26% | $5.39B | 0.43% |
XLV | 60.38% | $34.14B | 0.09% |
PPH | 60.18% | $590.55M | 0.36% |
IYH | 59.55% | $2.71B | 0.39% |
HDV | 59.36% | $10.90B | 0.08% |
VHT | 58.77% | $15.31B | 0.09% |
FHLC | 58.75% | $2.42B | 0.084% |
IXJ | 58.00% | $3.72B | 0.41% |
SPHD | 55.63% | $3.13B | 0.3% |
DHS | 55.37% | $1.22B | 0.38% |
BBH | 53.94% | $329.40M | 0.35% |
RSPH | 53.73% | $727.92M | 0.4% |
IHE | 52.33% | $557.07M | 0.39% |
SCHD | 52.28% | $68.70B | 0.06% |
SPYD | 51.06% | $6.80B | 0.07% |
IBB | 50.50% | $5.36B | 0.45% |
DIV | 49.55% | $642.76M | 0.45% |
LVHD | 49.52% | $561.47M | 0.27% |
CDC | 49.46% | $728.75M | 0.42% |
FBT | 49.37% | $1.01B | 0.54% |
Double maintains 15 strategies that include ABBV - AbbVie, Inc.
Current Value
$182.431 Year Return
Current Value
$182.431 Year Return